vs
Side-by-side financial comparison of MAYS J W INC (MAYS) and Protalix BioTherapeutics, Inc. (PLX). Click either name above to swap in a different company.
Protalix BioTherapeutics, Inc. is the larger business by last-quarter revenue ($9.1M vs $5.2M, roughly 1.8× MAYS J W INC). MAYS J W INC runs the higher net margin — -9.8% vs -60.3%, a 50.6% gap on every dollar of revenue. On growth, MAYS J W INC posted the faster year-over-year revenue change (-7.7% vs -49.9%). Protalix BioTherapeutics, Inc. produced more free cash flow last quarter ($1.6M vs $-1.7M). Over the past eight quarters, MAYS J W INC's revenue compounded faster (-1.4% CAGR vs -6.7%).
J.W. Mays, Inc. is a real estate firm based in Brooklyn, New York, United States. From 1927 until 1988 the company ran a chain of discount department stores in the area surrounding New York City referred to as Mays, with stores located in three of New York City's five boroughs, Long Island, and Putnam County. At its height as a retailer, the firm had 5000 employees working in 9 stores during the early 1970s.
Protalix BioTherapeutics is an Israeli pharmaceutical company that manufactures a plant-based enzyme, taliglucerase alfa, which has received U.S. Food and Drug Administration approval for the treatment of Gaucher disease.
MAYS vs PLX — Head-to-Head
Income Statement — Q2 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $5.2M | $9.1M |
| Net Profit | $-509.0K | $-5.5M |
| Gross Margin | — | 49.4% |
| Operating Margin | -13.7% | -51.1% |
| Net Margin | -9.8% | -60.3% |
| Revenue YoY | -7.7% | -49.9% |
| Net Profit YoY | -222.8% | -184.8% |
| EPS (diluted) | $-0.25 | $-0.06 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $5.2M | — | ||
| Q4 25 | $5.3M | $9.1M | ||
| Q3 25 | $5.7M | $17.9M | ||
| Q2 25 | $5.6M | $15.7M | ||
| Q1 25 | $5.6M | $10.1M | ||
| Q4 24 | $5.5M | $18.2M | ||
| Q3 24 | $5.5M | $18.0M | ||
| Q2 24 | $5.4M | $13.5M |
| Q1 26 | $-509.0K | — | ||
| Q4 25 | $-334.0K | $-5.5M | ||
| Q3 25 | $-92.0K | $2.4M | ||
| Q2 25 | $86.8K | $164.0K | ||
| Q1 25 | $-157.7K | $-3.6M | ||
| Q4 24 | $26.7K | $6.5M | ||
| Q3 24 | $-31.1K | $3.2M | ||
| Q2 24 | $-84.9K | $-2.2M |
| Q1 26 | — | — | ||
| Q4 25 | — | 49.4% | ||
| Q3 25 | — | 53.4% | ||
| Q2 25 | — | 62.5% | ||
| Q1 25 | — | 19.1% | ||
| Q4 24 | — | 78.7% | ||
| Q3 24 | — | 53.4% | ||
| Q2 24 | — | 29.8% |
| Q1 26 | -13.7% | — | ||
| Q4 25 | -9.3% | -51.1% | ||
| Q3 25 | -2.4% | 11.9% | ||
| Q2 25 | 2.0% | 7.5% | ||
| Q1 25 | -3.2% | -41.0% | ||
| Q4 24 | 0.9% | 39.6% | ||
| Q3 24 | -1.5% | 22.2% | ||
| Q2 24 | -2.9% | -18.0% |
| Q1 26 | -9.8% | — | ||
| Q4 25 | -6.4% | -60.3% | ||
| Q3 25 | -1.6% | 13.2% | ||
| Q2 25 | 1.5% | 1.0% | ||
| Q1 25 | -2.8% | -35.8% | ||
| Q4 24 | 0.5% | 35.6% | ||
| Q3 24 | -0.6% | 18.0% | ||
| Q2 24 | -1.6% | -16.4% |
| Q1 26 | $-0.25 | — | ||
| Q4 25 | $-0.17 | $-0.06 | ||
| Q3 25 | $-0.04 | $0.03 | ||
| Q2 25 | $0.04 | $0.00 | ||
| Q1 25 | $-0.08 | $-0.05 | ||
| Q4 24 | $0.01 | $0.10 | ||
| Q3 24 | $-0.02 | $0.03 | ||
| Q2 24 | $-0.04 | $-0.03 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $434.4K | $14.7M |
| Total DebtLower is stronger | $3.2M | — |
| Stockholders' EquityBook value | $51.9M | $48.2M |
| Total Assets | $88.4M | $82.3M |
| Debt / EquityLower = less leverage | 0.06× | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $434.4K | — | ||
| Q4 25 | $2.2M | $14.7M | ||
| Q3 25 | $748.6K | $13.6M | ||
| Q2 25 | $2.3M | $17.9M | ||
| Q1 25 | $1.5M | $19.5M | ||
| Q4 24 | $2.3M | $19.8M | ||
| Q3 24 | $1.2M | $27.4M | ||
| Q2 24 | $1.2M | $23.4M |
| Q1 26 | $3.2M | — | ||
| Q4 25 | $3.2M | — | ||
| Q3 25 | $3.2M | — | ||
| Q2 25 | $3.3M | — | ||
| Q1 25 | $3.3M | — | ||
| Q4 24 | $3.5M | — | ||
| Q3 24 | $3.9M | — | ||
| Q2 24 | — | — |
| Q1 26 | $51.9M | — | ||
| Q4 25 | $52.4M | $48.2M | ||
| Q3 25 | $52.8M | $52.9M | ||
| Q2 25 | $52.9M | $49.9M | ||
| Q1 25 | $52.8M | $45.2M | ||
| Q4 24 | $52.9M | $43.2M | ||
| Q3 24 | $52.9M | $32.4M | ||
| Q2 24 | $52.9M | $28.6M |
| Q1 26 | $88.4M | — | ||
| Q4 25 | $88.7M | $82.3M | ||
| Q3 25 | $88.0M | $82.3M | ||
| Q2 25 | $87.9M | $78.5M | ||
| Q1 25 | $88.3M | $73.9M | ||
| Q4 24 | $88.5M | $73.4M | ||
| Q3 24 | $89.5M | $61.6M | ||
| Q2 24 | $90.4M | $91.5M |
| Q1 26 | 0.06× | — | ||
| Q4 25 | 0.06× | — | ||
| Q3 25 | 0.06× | — | ||
| Q2 25 | 0.06× | — | ||
| Q1 25 | 0.06× | — | ||
| Q4 24 | 0.07× | — | ||
| Q3 24 | 0.07× | — | ||
| Q2 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-730.1K | $2.0M |
| Free Cash FlowOCF − Capex | $-1.7M | $1.6M |
| FCF MarginFCF / Revenue | -32.9% | 17.8% |
| Capex IntensityCapex / Revenue | 18.9% | 4.4% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $794.1K | $-13.6M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $-730.1K | — | ||
| Q4 25 | $1.9M | $2.0M | ||
| Q3 25 | $2.5M | $-3.7M | ||
| Q2 25 | $1.9M | $-5.2M | ||
| Q1 25 | $-383.4K | $-5.1M | ||
| Q4 24 | $1.8M | $4.0M | ||
| Q3 24 | $1.4M | $4.1M | ||
| Q2 24 | $2.0M | $-3.6M |
| Q1 26 | $-1.7M | — | ||
| Q4 25 | $1.5M | $1.6M | ||
| Q3 25 | $128.3K | $-4.2M | ||
| Q2 25 | $868.4K | $-5.7M | ||
| Q1 25 | $-586.2K | $-5.4M | ||
| Q4 24 | $1.3M | $3.6M | ||
| Q3 24 | $-1.0M | $4.0M | ||
| Q2 24 | $789.9K | $-3.8M |
| Q1 26 | -32.9% | — | ||
| Q4 25 | 28.8% | 17.8% | ||
| Q3 25 | 2.3% | -23.7% | ||
| Q2 25 | 15.4% | -36.2% | ||
| Q1 25 | -10.4% | -53.0% | ||
| Q4 24 | 24.2% | 19.6% | ||
| Q3 24 | -19.1% | 22.4% | ||
| Q2 24 | 14.7% | -28.1% |
| Q1 26 | 18.9% | — | ||
| Q4 25 | 7.8% | 4.4% | ||
| Q3 25 | 42.3% | 2.8% | ||
| Q2 25 | 18.8% | 2.8% | ||
| Q1 25 | 3.6% | 3.0% | ||
| Q4 24 | 8.3% | 2.3% | ||
| Q3 24 | 45.2% | 0.5% | ||
| Q2 24 | 21.9% | 1.3% |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | -1.58× | ||
| Q2 25 | 22.22× | -31.91× | ||
| Q1 25 | — | — | ||
| Q4 24 | 67.62× | 0.61× | ||
| Q3 24 | — | 1.27× | ||
| Q2 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
MAYS
Segment breakdown not available.
PLX
| Products | $8.7M | 95% |
| Other | $428.0K | 5% |
